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Abstract Gastric cancer is a signiWcant cause of morbid-
ity and mortality worldwide. Surgical resection remains the
primary curative treatment for gastric adenocarcinoma, but
the poor (15–35%) survival rate at 5 years has prompted
many studies for new therapeutic strategies, such as speciWc
immunotherapy. The aim of this study was to analyze the
functional properties of the T cell response to diVerent anti-
gen peptides related to gastric cancer in patients with gas-
tric adenocarcinoma. To this purpose, we have cloned and
characterized tumor-inWltrating T cells (TILs) isolated from
the neoplastic gastric tissue samples. A T cell response spe-
ciWc to diVerent peptides of gastric cancer antigens tested
was documented in 17 out of 20 patients, selected for their
HLA-A02 and/or -A24 alleles. Most of the cancer peptide-
speciWc TILs expressed a Th1/Tc1 proWle and cytotoxic
activity against target cells. The eVector functions of cancer
peptide-speciWc T cells obtained from the peripheral blood
of the same patients were also studied. The majority of
peripheral blood peptide-speciWc T cells also expressed the
Th1/Tc1 functional proWle. In conclusion, in most of the
patients with gastric adenocarcinoma, a speciWc type-1 T
cell response to gastric cancer antigens was detectable and
would have the potential of hamper tumor cell growth.
However, in order to get tumor cell killing in vivo, the
activity and the number of cancer peptide-speciWc Th1/Tc1
cells probably need to be enhanced by vaccination with the
appropriate cancer antigenic peptides or by injection of the
autologus tumor peptide-speciWc T cells expanded in vitro.
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Abbreviations
GCAA Gastric cancer antigen-associated peptides
PBMC Peripheral blood mononuclear cells
Th1 and Th0 Type 1 and type 0 helper CD4+ T cells
Tc1 and Tc0 Type 1 and type 0 cytotoxic CD8+ T cells
TILs Tumor-inWltrating lymphocytes
Introduction
Gastric cancer is a signiWcant cause of morbidity and
mortality worldwide [11]. It remains the second most
frequently diagnosed cancer in the world, accounting for
10% of all new cancer diagnoses. It has been estimated that
there will be more than 870,000 deaths for this disease in
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1820 Cancer Immunol Immunother (2009) 58:1819–1830the year 2010, accounting for approximately 12% of all
cancer deaths [20].
Gastric cancer is the end result of the interplay of many
risk factors as well as of protective factors. Genetic and
environmental elements are likely to play a role in the etiol-
ogy of the disease. Several factors are suspected to play a
role in gastric carcinogenesis, including the eVects of diet,
e.g., the low intake of animal fats and proteins is associated
with a decreased risk of cancer development [25]. Infec-
tious agents, particularly Helicobacter pylori, may also
play a role [14, 42]. H. pylori-mediated events, such as pro-
duction of reactive oxygen radicals, activation of growth
factors and cytokines, and alterations of signal transduction
processes are potential risk factors for gastric adenocarci-
noma [35, 41]. Hereditary elements increase as well the risk
of gastric cancer and this malignancy is part of a number of
familial cancer syndromes, the most celebrated case being
Napoleon Bonaparte [24]. Also the polymorphism of Inter-
leukin(IL)-1 and IL-8 genes has been associated with
increased risk of gastric cancer [10, 40].
Surgical tumor resection remains the primary curative
treatment for gastric cancer. Nevertheless, the overall 5-year
survival rate remains poor, ranging between 15 and 35%.
Among patients who relapse after curative surgery, the 87%
have locoregional recurrences [43].
These facts have prompted many studies addressing sur-
gical issues, as well as exploring the role of adjuvant and
neoadjuvant treatments, such as perioperative chemother-
apy, which associate with a 5-year overall survival beneWt
of 13% for stage II or III operable gastric cancer patients
[1]. Worldwide, despite the improvements, estimated cure
rates for patients with stages IIIA and IIIB remain poor
[23]. These data highlight the urgent need of new therapeu-
tic strategies to combat gastric cancer, such as epithelial
growth factor receptor (EGFR) inhibitors [49], anti-angio-
genetic agents [46], apoptosis promoters [39] and speciWc
immunotherapy [9].
The Wght against gastric cancer has adopted several
approaches to exploit the cancer-speciWc immune response
[9], such as patient vaccination with dendritic cells pulsed
with HER-2/neu-derived peptides [21] and vaccination by
injection of peptides of tumor-associated antigens [44, 45]. In
various studies of gastric cancer immunotherapy, there were
positive eVects for only a few patients. The disparities regis-
tered in cancer immunotherapy trials might be due to a diVer-
ent degree or type of immune response to the tumor antigens
in individual patients. The functional properties of the gastric
cancer antigen-speciWc T cells have not yet fully elucidated.
The aim of this study was to characterize the eVector
functions of the gastric cancer-associated antigen (GCAA)
peptide-speciWc T cells, isolated from either the gastric can-
cer tissue or the peripheral blood of patients with gastric
adenocarcinoma.
Materials and methods
Patients
Twenty patients (mean age 68 years) were enrolled in the
study. Fully informed consent and approval of the local
Ethical Committee were obtained. The characteristics of the
patients are summarized in Table 1. Patients were selected
on the basis of their HLA-A02 and/or HLA-A24 alleles. In
all patients the diagnosis of gastric adenocarcinoma was
conWrmed at pathology: 8 cases had the diVuse type cancer,
and 12 had the intestinal type. Patients underwent surgical
resection of the primary lesion and did not receive chemo-
therapy. Gastric biopsies were obtained by endoscopy from
15 patients with chronic gastritis (mean age 65 years) and
HLA-A02 and/or HLA-A24 alleles (disease controls).
Patients with the evidence of serious illness, immunosup-
pression, autoimmune or infectious diseases were excluded.
Reagents
Recombinant human IL-2 was a kind gift from Eurocetus
(Milan, Italy). PHA (M form) was purchased from Gibco
Laboratories (Grand Island, USA), ionomycin and phorbol
12-myristate 13-acetate (PMA) from Sigma (St. Louis,
USA). Anti-CD3, anti-CD4, anti-CD8, anti-IFN-, anti-IL-4,
anti-CD28 and anti-CD49d monoclonal antibodies (mAbs)
were purchased from BD Biosciences (San Jose, USA); the
mAbs anti-HLA-DR and anti-HLA-A-B-C were purchased
from Immunotech (Beckman Coulter, Marseille, France).
The peptides of gastric cancer-associated antigens (GCAA)
used in the present study were prepared by Multiple Peptide
System (San Diego, USA). The sequences of the GCAA
peptides are reported in Table 2. All these peptides have
proven the ability to induce HLA-A02- or HLA-A24-
restricted and tumor-speciWc cytotoxic lymphocyte activity
in the PBMCs of gastric cancer patients [27, 47, 51].
Generation of T cell clones from TILs of the neoplastic 
gastric tissue
Surgical specimens of gastric cancer tissue or endo-
scopic biopsy samples from the gastric mucosa of con-
trol patients with chronic gastritis were cultured for
7 days in RPMI 1640 medium supplemented with IL-2
(50 U/ml) in order to expand in vivo-activated TILs.
Specimens were then disrupted, and single T cell blast
was cloned under limiting dilution, as described [4].
BrieXy, single T cell blasts were seeded in microwells
(0.3 cells/well) in the presence of 2 £ 105 irradiated
(5,000 rad) PBMC, PHA (0.5% vol/vol), and IL-2 (50 U/ml).
At weekly intervals, 2 £ 105 irradiated PBMC and IL-2
were added to each microculture to maintain the expansion123
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responsiveness to GCAA peptides by measuring
[3H]thymidine (Amersham Pharmacia Biotech, Uppsala,
Sweden) uptake after 60-h co-culture with irradiated
autologous mononuclear cells in the presence of medium
or GCAA peptides (10 g/ml). The mitogenic index
(MI) was calculated as the ratio between mean values of
cpm obtained in stimulated cultures and those obtained
in the presence of medium alone. A MI ¸5 was consid-
ered as positive.
Analysis of TCR Vß chain repertoire of GCAA 
peptide-speciWc T cell clones
The repertoire of the TCR Vß chain of GCAA peptide-spe-
ciWc T cell clones was analyzed with a panel of 24 mAbs
Table 1 HLA-A allele, gastric 
pathology and GCAA peptide 
reactivity of T cell clones 
generated from TILs isolated 
from the neoplastic tissue of 
gastric adenocarcinoma (GA) 
patients or from gastric mucosa-
inWltrating T cells of patients 
with chronic gastritis (CG)
Code Sex/age HLA-A allele Gastric pathology No. of clones obtained
CD4+ CD8+
No. of peptide-reactive clones
01.BB 72 M A02-A24 DiVuse type GA 0/15 0/10
02.CC 66 M A02-A24 DiVuse type GA 4/26 4/18
03.CA 63 F A02 DiVuse type GA 4/23 2/18
04.FM 66 M A02 DiVuse type GA 4/23 3/19
05.PF 63 M A24 DiVuse type GA 5/26 4/15
06.Can 65 F A24 DiVuse type GA 2/20 3/12
07.CS 68 M A24 DiVuse type GA 0/18 0/11
08.DN 65 F A24 DiVuse type GA 4/25 4/15
09.BG 74 M A02-A24 Intestinal type GA 3/27 4/19
10.BA 74 M A02-A24 Intestinal type GA 3/21 4/17
11.BS 63 M A02-A24 Intestinal type GA 4/24 3/14
12.BGi 62 M A02 Intestinal type GA 4/22 4/18
13.MS 64 F A02 Intestinal type GA 3/18 3/14
14.AC 62 M A02 Intestinal type GA 4/22 4/15
15.PM 64 F A02 Intestinal type GA 4/24 3/20
16.MG 79 F A02 Intestinal type GA 0/16 0/11
17.MM 65 F A02 Intestinal type GA 4/23 3/12
18.SB 71 F A24 Intestinal type GA 4/21 5/17
19.AB 77 M A24 Intestinal type GA 5/23 3/20
20.BF 60 M A24 Intestinal type GA 4/22 3/21
All GA patients 65/437 59/316
21.GG 71 M A02-A24 Chronic gastritis 0/17 0/7
22.CJ 74 F A02-A24 Chronic gastritis 0/15 0/6
23.BU 71 M A02-A24 Chronic gastritis 0/22 0/8
24.LL 61 F A02 Chronic gastritis 0/25 0/10
25.AG 65 M A02 Chronic gastritis 0/18 0/8
26.TS 65 F A02 Chronic gastritis 0/22 0/11
27.VA 62 F A02 Chronic gastritis 0/14 0/8
28.TF 62 M A02 Chronic gastritis 0/17 0/8
29.CZ 62 F A02 Chronic gastritis 0/15 0/6
30.PL 59 M A24 Chronic gastritis 0/22 0/11
31.SF 75 M A24 Chronic gastritis 0/20 0/9
32.ZF 64 M A24 Chronic gastritis 0/19 0/7
33.VV 64 M A24 Chronic gastritis 0/19 0/9
34.LS 63 M A24 Chronic gastritis 0/21 0/8
35.PO 62 F A24 Chronic gastritis 0/16 0/4
All CG patients 0/282 0/120
GA gastric adenocarcinoma123
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Vß5.2, Vß5.3, Vß7.1, Vß7.2, Vß8, Vß9, Vß11, Vß12,
Vß13.1, Vß13.2, Vß13.6, Vß14, Vß16, Vß17, Vß18, Vß20,
Vß21.3, Vß22 and Vß23 (TCR Vß Repertoire Kit, Beck-
man Coulter, Fullerton, USA); Isotype-matched non-
speciWc Ig was used as negative control. Data acquisition
was performed in a FACScan Xow cytometer using the
Diva software program (Becton Dickinson).
Detection of GCAA peptide-speciWc T cells
in the peripheral blood of patients with gastric cancer
To test the presence of GCAA peptide-speciWc T cells in
the peripheral blood of patients with gastric adenocarci-
noma, PBMCs obtained by density gradient centrifugation
on Ficoll-Hypaque were resuspended in medium with 3%
human serum. PBMCs (3 £ 105) were cultured for 96 h in
the presence of medium alone or single GCAA peptides
(10 g/ml). At 16 h before harvesting, 0.5 Ci/well
[3H]thymidine was added, and the radionuclide uptake was
measured by a -counter. A MI >5 was considered as
positive.
CytoXuorimetric analysis of T cell surface markers 
and characterization of the cytokine proWle of GCAA 
peptide-speciWc T cell clones
Cell surface marker analysis of T cells was carried out by
two- or three-color Xow cytometry using Xuorochrome-
conjugated anti-CD3, anti-CD4, anti-CD8. The cells were
analyzed on a BD FACScan cytoXuorimeter using the Diva
software (BD Biosciences, San Jose, USA). A total of 104
events for each sample were acquired.
To induce the cytokine production by GCAA peptide-
speciWc T cell clones, 106 T cell blasts of each clone were
co-cultured for 48 h in 1 ml medium with 5 £ 105 irradi-
ated autologous PBMCs as antigen presentig cells (APC)
with or without single GCAA peptides (10 g/ml).
To elicit cytokine production by non-GCAA-speciWc T
cell clones, T cell blasts were resuspended at 106/ml
medium and cultured for 36 h in the presence of PMA
(10 ng/ml) plus ionomycin (200 ng/ml). Cell-free superna-
tants were collected and assayed in duplicate for IFN- and
IL-4 content by commercial ELISA assays (Bio-Source
International, Camarillo). Supernatants showing IFN- or
Table 2 Tumor associated anti-
gens and peptide sequences Antigen [Ref.] Peptide sequence and HLA restriction
HLA-A24 HLA-A02
SART1 [47] SART1-690 (EYRGFTQDF)
SART2 [34] SART2-93 (DYSARWNEI)
SART2-161 (AYDFLYNYL)
SART2-899 (SYTRLFLIL)
SART3 [51] SART3-109 (VYDYNCHVDL) SART3-302 (LLQAEAPRL)
SART3-315 (AYIDFEMKI) SART3-309 (RLAEYQAYI)
CypB [13] CypB-84 (KFHRVIKDF) CypB-129 (KLKHYGPGWV)
CypB-91 (DFMIQGGDF) CypB-172 (VLEGMEVV)
lck [16] lck-208 (HYTNASDGL) lck-246 (KLVERLGAA)
lck-486 (TFDYLRSVL) lck-422 (DVWSFGILL)
lck-488 (DYLRSVLEDF)
ART-1 [38] ART1-170 (EYCLKFTKL)
ART-4 [19] ART4-13 (AFLRHAAL)
ART4-75 (DYPSLSATDI)
EIF-4EBP [45] EIF-4EBP-51 (RIIYDRKFL)
ppMAPkkk [17] ppMAPkkk-294 (GLLFLHTRT)
ppMAPkkk-432 (DLLSHAFFA)
WHSC2 [27] WHSC2-103 (ASLDSDPWV)
WHSC2-141 (ILGELREKV)
UBE2V [17] UBE2V-43 (RLQEWCSVI)
UBE2V-85 (LIADFLSGL)
UBE2V-208 (ILPRKHHRI)
HNRPL [17] HNRPL-140 (ALVEFEDVL)
HNRPL-501 (NVLHFFNAPL)
SART squamous cell carcinoma 
antigen recognized by T cells, 
CypB cyclophilin B, 
lck leukocyte-speciWc protein 
tyrosine kinase, ART adenocar-
cinoma antigen recognized by 
T cells, EIF-4EBP eukaryotic 
translation Initiation factor-4E 
binding protein, ppMAPkkk 
partial putative mitogen-
activated protein kinase kinase 
kinase, WHSC2 Wolf-
Hirschhorn syndrome candidate 
2 protein, UBE2V ubiquitin-
conjugating enzyme variant kua, 
HNRPL heterogeneous nuclear 
ribonucleoprotein L123
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tants derived from irradiated APC alone were regarded as
positive. CD4+ and CD8+ T cell clones able to produce
IFN-, but not IL-4, were categorized as Th1 or Tc1,
respectively, whereas clones able to produce both IL-4 and
IFN-, as Th0 or Tc0, respectively.
Preparation of Epstein–Barr virus transformed (EBV-B) 
cells
B cell-enriched suspensions were prepared by a double-step
rosetting with neuraminidase-treated sheep erythrocytes, as
described elsewhere [6]. Peripheral blood B cell-enriched
suspensions usually consisted of 68–87% B cells, 9–21%
monocytes, and ·1% T cells. They will be referred to as B
cells. To obtain EBV-transformed lymphoblastoid B cell
lines, B cells were incubated for 48 h with supernatant of
the EBV-producing marmoset cell line B95.8 and subse-
quently expanded in complete medium supplemented with
15% FCS.
Perforin-mediated cytotoxicity and Fas–Fas 
Ligand(L)-mediated proapoptotic activity
Perforin-mediated cytolytic activity of T cell clones was
assessed as reported [5]. T cell blasts of GCAA peptide-spe-
ciWc clones were incubated at eVector to target ratios of 10, 5,
and 2.5–1 with 51Cr-labeled autologous EBV-B cells prein-
cubated with peptide (10 g/ml). After centrifugation, micro-
plates were incubated for 8 h at 37°C, and 0.1 ml supernatant
was removed from each microculture for measurement of
51Cr release. The ability of GCAA peptide-speciWc T cell
clones to induce Fas–FasL-mediated apoptosis was assessed
using Fas+ Jurkat cells as target [50]. T cell blasts from each
clone were co-cultured with 51Cr-labeled Jurkat cells at eVec-
tor to target ratios of 10, 5, and 2.5–1 for 18 h in the presence
of PMA (10 ng/ml) and ionomycin (1 mmol/l), as reported
[4]. To block Fas–FasL interaction, the anti-Fas antagonistic
monoclonal antibody M3 (Amgen, Thousand Oaks, USA)
was used at a 5 g/ml Wnal concentration in a 30-min pre-
treatment of 51Cr-labeled Jurkat cells, as reported [3].
Generation of GCAA peptide-speciWc T cell lines
Peptide-speciWc T cell lines were generated as described
[7]. BrieXy, 106 PBMC in 2 ml RPMI 1640 medium sup-
plemented with 2 mM L-glutamine, 2 £ 10¡5 M 2-ME, and
5% human serum (complete medium) were stimulated with
single GCAA peptides (10 g/ml) in 24-well Xat-bottom
plates for 5 days. Human IL-2 (30 U/ml) was then added,
and cultures were continued for 7 days. Viable T cell blasts
were resuspended in complete medium and tested for their
intracytoplasmatic cytokine expression.
CytoXuorometric analysis of the intracytoplasmic cytokine 
production of the GCAA peptide-speciWc T cell lines
CytoXuorometric analysis of intracytoplasmic IFN- and
IL-4 synthesis in GCAA peptide-speciWc T cell lines was
performed after 10 days of culture. BrieXy, after washing
with PBS, 1 £ 106 T cell blasts were stimulated with single
peptides (10 g/ml) plus anti-human CD28 (1 g/ml) and
anti-human CD49d (1 g/ml) for 6 h, being the last two
mAbs added in the presence of brefeldin A (5 g/ml). After
incubation, cells were washed twice with PBS, pH 7.2,
Wxed 15 min with formaldehyde (2% in PBS, pH 7.2),
washed twice with 0.5% BSA in PBS, pH 7.2, permeabili-
zed with PBS, pH 7.2, containing 0.5% BSA and 0.5%
saponin, and then incubated with the speciWc mAbs. Cells
were analyzed on a FACScan cytoXuorometer using the
Diva software. The area of positivity was determined using
an isotype-matched mAb. In all cytoXuorometric analysis, a
total of 104 events, gated as CD3+CD4+ or CD3+CD8+
cells, for each sample, were acquired.
Results
GCAA peptide-speciWc T cells inWltrate the neoplastic 
tissue of patients with gastric adenocarcinoma
T cell clones derived from the TILs of gastric cancer
patients were assayed for proliferation in response to each
of the GCAA peptides reported in Table 2. Among the 437
CD4+ TIL-derived T cell clones, 65 (15%) (Table 1) prolif-
erated to diVerent GCAA peptides. Of the 65 peptide-spe-
ciWc CD4+ T cell clones, 30 were activated by peptides
restricted by HLA-A24, whereas the other 35 recognized
their target peptide in the context of HLA-A02 (Table 1;
Fig. 1). Among the 316 CD8+ T cell clones generated from
the TILs of gastric cancer (Table 1), 59 (18%) proliferated
to GCAA peptides: namely, 29 CD8+ clones responded to
peptides restricted by HLA-A24 and 30 to peptides
restricted by HLA-A02 (Table 1; Fig. 1). Under the same
experimental conditions, none of the 282 CD4+ and none of
the 120 CD8+ T cell clones obtained from endoscopic biop-
sies of the gastric mucosa of patients with chronic gastritis
showed signiWcant proliferation to any GCAA peptide
(Table 1). As shown in Fig. 1, in the series of TIL-derived
clones, we found CD4+ and/or CD8+ clones reactive to one
or more peptides of the panel of GCAA peptides used in
this study (Table 3), those of antigens SART and lck having
higher chance to be recognized by the clonal progenies of
TILs from our patients. However, in three patients (1.BB,
7.CS, and 16.MG) (15%) we were unable to isolate any T
cell clone speciWc for any of the GCAA peptides used in
this study. Evidence for clonality of GCAA peptide-speciWc123
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of single TCR-Vß expression shown by those clones. Each
T cell clone was stained by only one of the TCR-Vß chain-
speciWc monoclonal antibodies, showing a single peak of
Xuorescence intensity (Fig. 2).
To assess whether the responses of CD4+ T cell clones
were HLA class I- or class II-restricted, cell proliferation
tests with GCAA peptides were performed in the presence
of autologous mononuclear cells and anti-HLA class I or
anti-HLA class II blocking mAbs (10 g/ml). On the basis
of the results obtained (Table 4), it is possible to conclude
that some TIL-derived CD4+ T cell clones (38 of 65, 58%)
showed an HLA class I-restricted response to GCAA pep-
tides, whereas the response of the rest of CD4+ clones (27
of 65, 42%) was HLA class II-restricted. The number of
peptide-speciWc CD4+ T cell clones that exhibited prolifera-
tion in a MHC class I manner is very restricted (one or two
per patient).
Fig. 1 Repertoire of TIL-derived T cell clones reactive to peptides
obtained from gastric cancer-associated antigens. Th1 and Th0 CD4+
clones (closed and open circles, respectively) and Tc1 and Tc0 CD8+
clones (closed and open squares, respectively) were tested for prolif-
eration to GCAA peptides in the presence of irradiated autologous
APCs. Results are expressed as mean values of mitogenic index
obtained in triplicate microcultures
Table 3 Cancer antigen peptide speciWcity of T cell clones generated
from TILs isolated from neoplastic tissue of gastric adenocarcinoma
patients
Patients Peptide-speciWcity of TIL-derived T cell clones in single 
patients
Number of reactive 
CD4+ clones
Number of reactive 
CD8+ clones
02.CC 2 SART3-315 2 SART2-93
1 SART3-309 1 CypB-172
1 lck-246 1 UBE2V-85
03.CA 3 lck-422 1 UBE2V-208
1 UBE2V-43 1 CypB-172
04.FM 3 CypB-172 2 lck-422
1 SART3-309 1 SART3-302
05.PF 2 SART2-93 2 lck-486
2 lck-208 1 lck-208
1 lck-488 1 SART2-93
06.CAn 2 CypB-84 2 CypB-84
1 ART4-13
08.DN 2 lck-208 3 SART3-109
2 SART3-109 1 CypB-84
09.BG 2 lck-246 2 lck-246
1 ART4-13 2 lck-486
10.BA 2 SART2-93 2 SART3-109
1 HNRPL-140 2 HNRPL-501
11.BS 2 SART2-161 1 SART2-161
2 HNRPL-140 1 SART3-315
1 CypB-84
12.BG 2 lck-422 2 SART3-302
1 SART3-302 2 UBE2V-85
1 UBE2V-85
13.MS 2 SART3-302 3 WHSC2-103
1 WHSC2-103
14.AC 2 HNRPL-501 2 lck-422
1 UBE2V-43 2 UBE2V-43
1 UBE2V-85
15.PM 2 SART3-302 1 SART3-302
2 lck-246 2 lck-246
17.MM 2 WHSC2-103 1 lck-422
2 HNRPL-501 2 HNRPL-501
18.SB 2 SART3-315 2 SART2-161
2 ART4-75 2 ART1-170
1 lck-208
19.AB 2 SART2-161 1 SART2-93
2 ART4-75 1 SART3-315
1 lck-488 1 lck-208
20.BF 3 SART3-309 2 SART3-109
1 SART2-93 1 CypB-84123
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clones showed an HLA class I-restricted response.
Th1/Tc1 eVector functions of TIL-derived T cell clones 
speciWc for GCAA peptides
The cytokine proWle induced in peptide-speciWc TIL-
derived T cell clones by stimulation with the appropriate
GCAA peptide in the presence of irradiated autologous
APC was then assessed. Upon stimulation with the speciWc
peptide, the majority of peptide-reactive CD4+ and/or CD8+
clones produced IFN-, but not Th2 cytokines, expressing
thus the Th1/Tc1 proWle, whereas 17% of CD4+ and 25% of
CD8+ clones expressed a Th0 or Tc0 proWle, respectively,
with production of both IFN- and IL-4 (Fig. 3).
Since most of antigen-activated Th1 and Th0 clones
express perforin-mediated cytotoxicity against autolo-
gous antigen-presenting APC (e.g., GCAA peptide-
pulsed B cells) [3], we assessed the cytolytic potential of
peptide-speciWc T cell clones using GCAA peptide-pulsed
Fig. 2 TCR Vß chain collection 
of GCAA peptides-speciWc 
T cell clones. The clonality of 
T cell clones reactive tumoral 
antigen peptides was analyzed 
by a panel of 24 monoclonal 
antibodies speciWc for human 
TCR Vß chain families, as 
detailed in “Materials and 
methods”. T cell blasts from 
each clone were divided in 
aliquots and stained with each of 
the monoclonal antibody and the 
appropriate isotype controls
Table 4 EVect of anti-HLA 
class I and II monoclonal 
antibodies on T cell clone 
proliferation induced 
by GCAA peptides
Phenotype of clones/
speciWc peptides
Peptide 
alone (MI § SD)
Peptide + anti-HLA 
class I (% inhibition)
Peptide + anti-HLA 
class II (% inhibition)
Culture conditions
CD4+/SART2-93 51.7 § 5.2 8.2 § 1.2 (84) 42.5 § 3.2 (18)
CD4+/lck-208 63.4 § 4.1 7.7 § 3.1 (88) 54.3 § 5.4 (14)
CD4+/lck-488 72.6 § 3.4 56.6 § 7.4 (12) 13.7 § 2.2 (81)
CD4+/ART4-13 52.3 § 3.7 14.2 § 2.3 (73) 41.1 § 9.1 (21)
CD4+/HNRPL-501 57.2 § 8.5 49.7 § 5.2 (13) 11.2 § 1.5 (80)
CD4+/UBE2V-43 62.3 § 2.5 12.4 § 4.3 (80) 47.7 § 8.7 (13)
CD8+/SART2-93 35.3 § 5.3 4.7 § 1.2 (87) 27.1 § 6.3 (13)
CD8+/lck-208 42.5 § 6.1 5.2 § 0.8 (88) 37.4 § 7.2 (12)
CD8+/lck-486 26.7 § 4.3 4.5 § 3.2 (83) 21.5 § 6.1 (19)
CD8+/CypB-172 33.5 § 3.8 8.3 § 1.2 (75) 29.5 § 4.8 (12)
CD8+/WHSC2-103 56.4 § 5.1 11.6 § 5.2 (79) 48.7 § 5.7 (14)
CD8+/HNRPL-501 47.3 § 5.6 6.7 § 1.1 (76) 38.9 § 3.9 (18)MI mitogenic index, SD standard deviation123
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eVector to target ratio of 10:1, all 50 CD4+ Th1 and 11 out
of the 15 Th0 CD4+ clones lysed GCAA peptide-presenting
autologous EBV-B cells (Fig. 4). Likewise, all the 59 CD8+
(44 Tc1 and 15 Tc0) T cell clones lysed GCAA peptide-
presenting autologous EBV-B cells, at an eVector to target
ratio of 10:1 or lower.
Because activated eVector T cells can also kill their tar-
gets by inducing apoptosis through Fas–FasL interaction
[50], the ability of activated peptide-speciWc T cell clones
to induce 51Cr release by Fas+ Jurkat cells undergoing
apoptosis was evaluated. Upon mitogen activation, 50 of 65
CD4+ (77%) and 50 (85%) out of 59 CD8+ clones were able
to induce apoptosis in target cells (Fig. 5). The role of Fas–
FasL interaction in the 51Cr release was conWrmed by its
inhibition (range 39.6–59.8%) using a blocking anti-Fas
antibody (data not shown).
GCAA peptide-speciWc T cells in the peripheral blood 
of patients with gastric cancer
In order to assess the presence of T cells speciWc for GCAA
peptides in the peripheral blood of patients with gastric ade-
nocarcinoma, PBMCs from all 20 patients were cultured
(3 £ 105) for 5 days in the presence of medium alone or
single GCAA peptides (10 g/ml) of the series. The PBMCs
of 14 patients (70%) with gastric adenocarcinoma prolifer-
ated in the presence of GCAA peptides (data not shown). In
particular, in four patients HLA-A02+/HLA-A24+ PBMCs
Fig. 3 Gastric cancer antigen peptide-induced cytokine production by
TIL-derived T cell clones. GCAA peptide-speciWc Th1 and Th0 CD4+
and Tc1 and Tc0 CD8+ T cell clones were stimulated with the appro-
priate peptides (10 g/ml), and IFN- and/or IL-4 production was mea-
sured in culture supernatants by speciWc ELISA assays. In supernatants
of control cultures stimulated with medium alone, levels of IFN- and
IL-4 were consistently <0.05 and <0.01 ng/ml. Dotted lines represent
3 SD over the mean levels of IFN- and IL-4 measured in control cul-
tures Fig. 4 Cancer antigen peptide-induced cytotoxicity of TIL-derived
peptide-speciWc CD4+ and CD8+ T cells clones. To assess their
perforin-mediated cytotoxicity, T cell clones were cocultured with
51Cr-labeled autologous EBV-B cells pulsed with the appropriate
GCAA peptides. Results represent mean values of percent speciWc 51Cr
release at an eVector to target ratio of 10–1 in triplicate microcultures.
The dotted line represents 3 SD over the mean 51Cr release in cultures
with 51Cr-labeled autologous EBV-B cells pulsed with medium alone
Fig. 5 Proapoptotic activity and cytotoxicity against gastric cancer
cells lines. Proapoptotic activity of TIL-derived cancer peptide-spe-
ciWc T cell clones. To assess their ability to induce apoptosis in target
cells, peptides-speciWc T cell clones were stimulated with mitogen
(open squares) or medium alone (open squares) and cocultured with
51Cr-labeled Fas+ Jurkat cells. 51Cr release was then measured as index
of apoptotic target cell death. Data of three representative clones are
reported. Results represent mean values (§SD)123
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HLA-A molecule, while in six patients HLA-A02+/HLA-
A24¡ proliferation occurred only upon stimulation with
HLA-A02 restricted peptides and in the six patients HLA-
A02¡/HLA-A24+ PBMCs recognized only HLA-A24
restricted GCAA peptides. The PBMCs from the remaining
six patients with gastric adenocarcinoma or from the 15
chronic gastritis patients did not proliferate to any of the
GCAA peptides tested.
Predominant Th1/Tc1 proWle of GCAA peptide-speciWc 
T cell lines derived from PBMCs of patients with gastric 
cancer
Upon 5-day stimulation of patient PBMC with single
GCAA peptides, peptide-speciWc T cell lines were
expanded with IL-2 for additional 7 days. Peptide-speciWc
T cell lines could be obtained from 16 out of the 20 patients
studied, whereas no viable T cell line was derived from
four of the six patients whose PBMCs did not proliferate to
any of the tumor peptides. Incidentally, three of those four
patients (1.BB, 7.CS and 16.MG) were the same in which
we failed to derive and expand any tumor antigen-speciWc
T cell clone. On day 10, viable T cell blasts of the peptide-
speciWc T cell lines were resuspended in complete medium
and tested for their intracytoplasmatic cytokine expression.
After stimulation with the appropriate HLA-A-restricted
peptide in the presence of costimulatory molecules (anti-
CD28 and anti-CD49d), all T cell lines included a remark-
able proportion of peptide-speciWc CD4+ and CD8+ Th1
(average 11%) and Tc1 (average 15%) cells able to produce
intracytoplasmic IFN-, but only a few Th0 and Tc0 cells
expressing both IFN- and IL-4 (Table 5). In other words,
the data from the peripheral blood conWrmed the Th1/Tc1
predominance of the GCAA peptide-speciWc T cells
derived from TILs of the gastric neoplastic tissues. It is
interesting that in almost all patients the peptides that
induced the production of IFN- in PBMC were the same
that stimulated the proliferation of the GCAA peptide-
speciWc T cell clones isolated from the neoplastic tissues.
Discussion
In this study, the T cell response speciWc to gastric cancer-
associated antigen (GCAA) peptides in 20 patients with
gastric adenocarcinoma was analyzed. The use of a series
of GCAA peptides allowed us to demonstrate the presence
among the gastric tumor-inWltrating lymphocytes of T cells
speciWc for GCAA peptides presented and restricted by
HLA-A02 and/or HLA-A24 histocompatibility molecules.
In view of the small number of TILs that can be recovered,
the study took advantage of a high eYciency cloning proce-
dure allowing the clonal expansion of virtually every single
T cell [30]. The analysis of the clonal progeny of TILs iso-
lated from the neoplastic tissue showed a large predomi-
nancy of both CD4+ and CD8+ T cell clones able to secrete
IFN-, whereas the concomitant production of IFN- and
IL-4 was limited to only a few clones. Therefore, the major-
ity of gastric cancer TILs speciWc for GCAA peptides
expressed the Th1 or Tc1 cytokine proWle, whereas a much
smaller proportion of GCAA peptide-speciWc TILs
expressed the Th0 or Tc0 proWle, according to their CD4 or
CD8 phenotype, respectively.
A reasonable question is whether this pattern does
indeed reXect the real functional behavior of gastric cancer
TILs in vivo, or it is the result of in vitro artifacts due to
culture in IL-2 and cloning procedure. In previous studies,
however, using the very same culture and cloning protocol,
T cell clones with predominant Th0 proWle were obtained
from the gastric mucosa of patients with chronic gastritis
[2] and T cell clones polarized into the Th2 proWle were
obtained from the bronchial inWltrates of patients with aller-
gic asthma [8].
Similar proportions of GCAA peptide-speciWc T cell
clones were derived from CD8+ (18%) and CD4+ (15%)
Table 5 Intracytoplasmic cytokine synthesis by cancer antigen pep-
tide-speciWc T cell lines generated from PBMC and stimulated with the
relevant GCAA peptide
Intracytoplasmic IL-4 and IFN- positive T cell blasts of PBMC-
derived peptide-speciWc T cell lines. GCAA peptide speciWc T cell
lines were obtained from 16 of 20 patients with gastric adenocarci-
noma. T cell blasts were stimulated with peptides (10 g/ml) and intra-
cellular cytokine synthesis was evaluated by cytoXuorometric analysis.
Results represent mean proportions of cytokine-positive cells over the
background values obtained with isotype-control monoclonal antibodies
Patients Proportion (%) of peptide-reactive T cell blasts expressing 
cytokines
CD4+ IFN-+ CD4+IL-4+ CD8+ IFN-+ CD8+IL-4+
02.CC 11.2 0.11 15.1 0.19
03.CA 12.1 <0.1 12.8 <0.1
04.FM 6.2 <0.1 10.3 <0.1
05.PF 10.0 0.10 11.9 0.18
06.CAn 11.9 <0.1 16.3 0.20
08.DN 10.9 0.20 13.9 0.10
09.BG 7.8 <0.1 10.0 <0.1
10.BA 10.3 <0.1 13.0 <0.1
11.BS 8.1 <0.1 9.1 <0.1
12.BG 8.9 <0.1 10.8 <0.1
13.MS 11.9 0.10 12.7 0.17
14.AC 7.0 <0.1 10.1 <0.1
17.MM 7.2 <0.1 10.3 0.39
18.SB 11.8 0.19 15.0 <0.1
19.AB 15.1 0.18 16.2 <0.1
20.BF 10.1 <0.1 11.4 <0.1123
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patients. Classically, CD4+ T cells recognize antigens pre-
sented by MHC class II molecules, whereas CD8+ T cells
recognize antigens presented by MHC class I molecules.
However, there are several reported exceptions to this rule
[5, 12, 37, 48]. Accordingly, in our present studies we have
found that a restricted number (one or two per patient)
of speciWc CD4+ T cell clones showed an HLA class
I-restricted response to GCAA peptides.
The series of peptide-speciWc TIL-derived T cell clones
included clones with diVerent speciWcity for HLA-A02 and/
or HLA-A24 restricted tumor antigen peptides. Although
the repertoire of peptide speciWcity of TIL-derived T cell
clones was wide (Table 3), including almost each of the
diVerent GCAA peptides tested, those speciWc for peptides
belonging to SART3 and lck cancer antigens were the
majority, being 24 and 32, respectively. For this aspect, our
results are in agrement with the data of previous studies,
which reported that the host immune response to gastric
cancer frequently target SART and lck tumor-associated-
antigens [16, 26, 33, 36].
The presence in the context of gastric cancer of cancer
antigen peptide-speciWc TILs suitable for detection and
clonal expansion is not a rule, because in up to 15% of our
gastric cancer patients it was not possible to isolate and to
expand any GCAA peptide-speciWc T cell clone, in spite
of their appropriate HLA-A02 and/or HLA-A24 alleles.
The simplest explanation for this failure is that a speciWc
T cell response against the tumor antigens was missing or
extremely poor in such patients because they were made
somehow ‘tolerant’ to their gastric cancer antigens. How-
ever, the mechanisms responsible for such an anergic or
tolerant state to gastric cancer remain unclear.
Using GCAA peptide-pulsed 51Cr-labeled autologous
EBV-B cells as targets, we could demonstrate that all the
CD8+ and 94% of CD4+ peptide-speciWc TIL-derived
clones were equipped with the cytotoxic machinery
required for the lysis of target cells. Furthermore, upon
mitogen activation, 81% of the GCAA peptide-speciWc TIL
clones were able to induce apoptosis in target cells by Fas–
FasL interaction.
Taken together these results conWrm that the TIL-
derived clones speciWc for GCAA peptides are able to
express a cancer peptide-speciWc cytotoxic activity, which
may represent an important pre-requisite for eVective gas-
tric cancer immunotherapy [29, 44].
In the second part of the study, we analyzed whether T
cells obtained from the peripheral blood of patients with
gastric adenocarcinoma might have similar eVector func-
tions to those of TILs obtained from the gastric neoplastic
lesions of the same patients. The presence of T cells spe-
ciWc for GCAA peptides in the peripheral blood has been
documented in 14 (70%) out of the 20 patients with gastric
cancer. For the six gastric cancer patients in which GCAA
peptide-speciWc T cells were not detectable in the periphe-
ral blood, we suspect that their number was too small and
below the sensitivity of the methods used or that virtually
all the GCAA peptide-speciWc T cells homed into the neo-
plastic tissue, without consistent recirculation to the periph-
ery. Of interest is the observation that among the six
patients apparently lacking peptide-speciWc T cells in their
peripheral blood, there were three patients (1.BB, 7.CS and
16.MG) in which we were unable to isolate and expand
TIL-derived T cell clones speciWc for GCAA peptides, sug-
gesting that a number of gastric cancer patients can indeed
lack a cancer-speciWc T cell response, as already suggested
in recent studies [18, 31].
Finally, we assessed the cytokine proWle of GCAA pep-
tide-speciWc T cells isolated from the peripheral blood of
gastric cancer patients, and for each patient single GCAA
peptides were used to induce speciWc T cell lines which have
been subsequently studied by intracytoplasmic cytoXuoro-
metric analysis. In most of the patients (16 out of 20) we
obtained GCAA peptide-speciWc T cell lines that, upon
stimulation with the speciWc peptide, included a quite high
number of T cells expressing intracytoplasmic IFN-,
whereas T cells positive for intracytoplasmic IL-4 were very
few or missing. These data support the notion that the major-
ity of both gastric-derived and circulating T cells speciWc for
gastric cancer antigens tend to express a Th1 or Tc1 proWle.
In addition, the production of cytokines was induced by the
identical GCAA peptides that were able to evoke a speciWc
T cell response at intra-tumor level of the same patients.
Since in none of the three patients (1.BB, 7.CS and
16.MG) apparently lacking GCAA peptide-speciWc TILs,
in vitro stimulation with cancer peptides failed to generate
GCAA peptide-speciWc T cell lines, we favor the hypothe-
sis that those patients were actually unable to raise a T cell
immune response against their gastric adenocarcinoma. On
the other hand, the pre-vaccination screening proposed by
some studies [44] before generating peptides to be used for
anti-tumor vaccination can explain some of the negative
responses that are not caused by a lack of immune response
to cancer, but would be due to a small number of speciWc
T cells circulating in the body.
According to our in vitro data, almost all the TIL-
derived T cell clones isolated from gastric tumors showed a
strong cytotoxic activity, which, however, was not eVective
in vivo to block the growth and the progression of their gas-
tric cancer. A possible explanation of this discrepancy is
that the in vivo conditions of activation of cancer antigen-
speciWc T cells are quite diVerent from those achieved in
vitro, in which hampering of T cell response by regulatory
T cells, immunosuppressive cytokines or other suppressive
mechanisms are missing. Indeed, gastric cancer cells could
inactivate the T cell cytotoxic activity through various123
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factors of the T cell response [22, 32] or through inappro-
priate recruitment of regulatory T cells [15]. In the case of a
negative direct action of the tumor cells on the T cell
response, also immunotherapeutic vaccination would have
poor chance to be eVective [9].
This study provided evidence that the majority of
patients with gastric adenocarcinoma host in their neoplas-
tic tissue a T cell response speciWc for MHC-class I
restricted peptides belonging to tumor-associated antigens.
In agreement with previous studies [28] that correlated the
peptide-speciWc IgG levels in postvaccination sera with
prolonged survival in advanced cancer patients vaccinated
with peptides, we have demonstrated that a T cell GCAA
peptide-speciWc response is also detectable in the peripheral
blood, suggesting that TIL can recirculate in the periphery.
There are however some exceptions, i.e., patients who
apparently lack a T cell response to neoplastic antigens in
their peripheral blood, in spite of the presence of cancer
antigen-reactive T cells within the cancer tissue. Finally,
there are a few patients who apparently lack cancer antigen-
reactive T cells in either the tumor or the periphery.
Even though in most of the patients with gastric adeno-
carcinoma, a speciWc Th1/Tc1 cytotoxic T cell response to
cancer antigen peptides was detectable, their capacity of
hampering tumor cell growth was actually poor and ineVec-
tive in vivo. However, if the cancer peptide-speciWc Th1/
Tc1 response would be enhanced by vaccination with the
appropriate cancer peptides or by injection of autologous
GCAA peptide-speciWc T cells expanded in vitro, tumor
cell killing in vivo might become reasonably achievable.
Acknowledgments We wish to thank Istituto Superiore di Sanità,
Ente Cassa di Risparmio di Firenze and Italian Ministry of University
and Research for their support of our studies.
References
1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de
Velde CJ, Nicolson M, ScarVe JH, Lofts FJ, Falk SJ, Iveson TJ,
Smith DB, Langley RE, Verma M, Weeden S, Chua YJ (2006)
MAGIC trial participants perioperative chemotherapy versus sur-
gery alone for resectable gastroesophageal cancer. N Engl J Med
355:11–20
2. D’Elios MM, Manghetti M, Almerigogna F, Amedei A, Costa F,
Burroni D, Baldari CT, Romagnani S, Telford JL, Del Prete G
(1997) DiVerent cytokine proWle and antigen-speciWcity repertoire
in Helicobacter pylori-speciWc T cell clones from the antrum of
chronic gastritis patients with or without peptic ulcer. Eur J Immu-
nol 27:1751–1755
3. D’Elios MM, Amedei A, Manghetti M, Costa M, Baldari CT, Quazi
AS, Telford JL, Romagnani S, Del Prete G (1999) Impaired T-cell
regulation of B-cell growth in Helicobacter pylori-related gastric
low-grade MALT lymphoma. Gastroenterology 117:1105–1112
4. D’Elios MM, Bergman MP, Azzurri A, Amedei A, Benagiano M,
De Pont JJ, Cianchi F, Vandenbroucke-Grauls CM, Romagnani S,
Appelmelk BJ, Del Prete G (2001) H(+), K(+)-atpase (proton
pump) is the target autoantigen of Th1-type cytotoxic T cells in
autoimmune gastritis. Gastroenterology 120:377–386
5. Darrow TL, Abdel-Wahab Z, Quinn-Allen MA, Seigler HF (1996)
Recognition and lysis of human melanoma by a CD3+, CD4+,
CD8- T-cell clone restricted by HLA-A2. Cell Immunol 172:52–
59
6. Del Prete G, De Carli M, Ricci M, Romagnani S (1991) Helper
activity for immunoglobulin synthesis of T helper type I (Thl) and
Th2 human T cell clones: the help of Thl clones is limited by their
cytolytic capacity. J Exp Med I74:809–813
7. Del Prete G, De Carli M, Mastromauro C, Biagiotti R, Macchia D,
Falagiani P, Ricci M, Romagnani S (1991) PuriWed protein deriv-
ative of Mycobacterium tuberculosis and excretory–secretory anti-
gen(s) of Toxocara canis expand in vitro human T cells with stable
and opposite (type 1 T helper or type 2 T helper) proWle of cyto-
kine production. J Clin Invest 83:346–350
8. Del Prete G, De Carli M, D’Elios MM, Maestrelli P, Ricci M, Fab-
bri L, Romagnani S (1993) Allergen exposure induces the activa-
tion of allergen-speciWc Th2 cells in the airway mucosa of patients
with allergic respiratory disorders. Eur J Immunol 23:1445–1449
9. Elkord E, Hawkins RE, Stern PL (2008) Immunotherapy for gas-
trointestinal cancer: current status and strategies for improving
eYcacy. Expert Opin Biol Ther 8:385–395
10. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH,
Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon
G, Martin M, Fraumeni JF Jr, Rabkin CS (2000) Interleukin-1
polymorphisms associated with increased risk of gastric cancer.
Nature 404:398–402
11. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P
(2007) Estimates of the cancer incidence and mortality in Europe
in 2006. Ann Oncol 18:581–592
12. Ge Q, Holler PD, Mahajan VS, Nuygen T, Eisen HN, Chen J
(2006) Development of CD4+ T cells expressing a nominally
MHC class I-restricted T cell receptor by two diVerent mecha-
nisms. Proc Natl Acad Sci USA 103:1822–1827
13. Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S,
Hayashi A, Sobao Y, Oizumi K, Itoh K (1999) A cyclophilin B
gene encodes antigenic epitopes recognized by HLA-A24-restrict-
ed and tumor-speciWc cytotoxic T lymphocytes. J Immunol
163:4994–5004
14. RC IA (1994) IARC monograph on the evaluation of carcinogenic
risks to humans: Schistosomes, Liver Flukes and Helicobacter
pylori, vol 16. IARC, Lyon
15. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H
(2003) Increased populations of regulatory T cells in peripheral
blood and tumor-inWltrating lymphocytes in patients with gastric
and esophageal cancers. Clin Cancer Res 9:4404–4408
16. Imai N, Harashima N, Ito M, Miyagi Y, Harada M, Yamada A,
Itoh K (2001) IdentiWcation of Lck-derived peptides capable of
inducing HLA-A2-restricted and tumor-speciWc CTLs in cancer
patients with distant metastases. Int J Cancer 94:237–242
17. Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, Saito N, Itoh K
(2001) Molecular basis of T cell-mediated recognition of pancre-
atic cancer cells. Cancer Res 61:2038–2046
18. Kaper T, Looger LL, Takanaga H, Platten M, Steinman L,
Frommer WB (2007) Nanosensor detection of an immunoregula-
tory tryptophan inXux/kynurenine eZux cycle. PLoS Biol 5:e257
19. Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Itoh K,
Yamada A (2000) IdentiWcation of a new endoplasmic reticulum-
resident protein recognized by HLA-A24-restricted tumor inWl-
trating lymphocytes of lung cancer. Cancer Res 60:3550–3558
20. Kelley JR, John M (2003) Duggan Gastric cancer epidemiology
and risk factors. J Clin Epidemiol 56:1–9
21. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR,
Kiessling R, Matsumoto Y (2002) Dendritic cells pulsed with123
1830 Cancer Immunol Immunother (2009) 58:1819–1830HER-2/neu-derived peptides can induce speciWc T-cell responses
in patients with gastric cancer. Clin Cancer Res 8:3394–3400
22. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s
Achilles’ heel. Cancer Cell 13:472–482
23. Liakakos T, Roukos DH (2008) More controversy than ever-chal-
lenges and promises towards personalized treatment of gastric
cancer. Ann Surg Oncol 15:956–960
24. Marchall BJ, Windsor HM (2005) The relation of Helicobacter
pylori to gastric adenocarcinoma and lymphoma: pathophysiol-
ogy, epidemiology, screening, clinical presentation, treatment, and
prevention. Med Clin North Am 89:313–344
25. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD,
Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H,
West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr (2001) Nutrient
intake and risk of subtypes of esophageal and gastric cancer.
Cancer Epidemiol Biomarkers Prev 10:1055–1062
26. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M,
Uemura H, Itoh K, Harada M (2007) IdentiWcation of SART3-de-
rived peptides having the potential to induce cancer-reactive cyto-
toxic T lymphocytes from prostate cancer patients with HLA-A3
supertype alleles. Cancer Immunol Immunother 56:689–698
27. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T,
Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A,
Aizawa H, Shirouzu K, Itoh K, Yamana H (2003) Immunological
evaluation of CTL precursor-oriented vaccines for advanced lung
cancer patients. Cancer Sci 94:548–556
28. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N,
Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S,
Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K,
Yamana H (2004) Humoral responses to peptides correlate with
overall survival in advanced cancer patients vaccinated with pep-
tides based on pre-existing, peptide-speciWc cellular responses.
Clin Cancer Res 10:929–937
29. Mochizuki K, Sato Y, Tsuda N, Shomura H, Sakamoto M,
Matsuura K, Ushijima K, Maeda Y, Katagiri K, Yamada A,
Todo S, Kamura T, Harada M, Itoh K (2004) Immunological
evaluation of vaccination with pre-designated peptides frequently
selected as vaccine candidates in an individualized peptide vacci-
nation regimen. Int J Oncol 25:121–131
30. Moretta A, Pantaleo G, Moretta L, Cerottini JC, Mingari MC
(1983) Direct demonstration of the clonogenic potential of every
human peripheral blood T cell: clonal analysis of HLA-DR expres-
sion and cytolytic activity. J Exp Med 157:743–751
31. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E,
Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygen-
ase, an immunoregulatory target of the cancer suppression gene
Bin1, potentiates cancer chemotherapy. Nat Med 11:312–319
32. Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism
governed by myeloid-derived suppressor cells. Cancer Res
68:2561–2563
33. Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y,
Shirakusa T, Yamada A, Itoh K, Harada M (2007) IdentiWcation of
Lck-derived peptides applicable to anti-cancer vaccine for patients
with human leukocyte antigen-A3 supertype alleles. Br J Cancer
97:1648–1654
34. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K,
Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H,
Fujita H, Itoh K (2000) IdentiWcation of a gene coding for a new
squamous cell carcinoma antigen recognized by the CTL. J Immu-
nol 164:2565–2574
35. Naumann M, Crabtree JE (2004) Helicobacter pylori-induced epi-
thelial cell signaling in gastric carcinogenesis. Trends Microbiol
12:29–36
36. Niiya F, Nishizaka S, Matsunaga K, Koufuji K, Mori M, Katai H,
Yamana H, Itoh K (2000) Expression of SART3 tumor-rejection
antigen in gastric cancers. Jpn J Cancer Res 91:337–342
37. Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C,
Parkhurst MR, Diamond RA, Robbins PF, Schwartzentruber DJ,
Rosenberg SA (1999) MHC class I-restricted recognition of a mel-
anoma antigen by a human CD4+ tumor inWltrating lymphocyte.
Cancer Res 59:6230–6238
38. Nishizaka S, Gomi S, Harada K, Oizumi K, Itoh K, Shichijo S
(2000) A new tumor- rejection antigen recognized by cytotoxic T
lymphocytes inWltrating into a lung adenocarcinoma. Cancer Res
60:4830–4837
39. Ocean AJ, Schnoll-Sussman F, Keresztes R, Chen X, Holloway S,
Matthews N, Christos P, Mazumdar M, Wright J, Wadler S (2006)
Phase II study of PS-341 (bortezomib) with or without irinotecan
in patients (pts) with advanced gastric adenocarcinomas (AGA).
J Clin Oncol (20 June Supplement):14040
40. Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K,
Koike T, Sekine H, Ohara S, Shimosegawa T (2005) The polymor-
phism interleukin 8-251 A/T inXuences the susceptibility of Heli-
cobacter pylori related gastric diseases in the Japanese population.
Gut 54:330–335
41. Peek RM, Blaser MJ (2002) Helicobacter pylori and gastrointesti-
nal adenocarcinomas. Nat Rev Cancer 2:28–37
42. Rocco A, Nardone G (2007) Diet, H pylori infection and gastric
cancer: evidence and controversies. World J Gastroenterol
13:2901–2912
43. Roukos DH, Kappas AM (2005) Perspectives in the treatment of
gastric cancer. Nat Clin Pract Oncol 2:98–107
44. Sato Y, Shomura H, Maeda Y, Mine T, Une Y, Akasaka Y, Kondo
M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S,
Matsui K, Yamada A, Yamana H, Itoh K, Todo S (2003) Immuno-
logical evaluation of peptide vaccination for patients with gastric
cancer based on pre-existing cellular response to peptide. Cancer
Sci 94:802–808
45. Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y,
Tokunaga N, Ikeda Y, Ishihara Y, Yamada A, Tanaka N, Itoh K,
Harada M, Todo S (2007) Immunological evaluation of personal-
ized peptide vaccination in combination with a 5-Xuorouracil
derivative (TS-1) for advanced gastric or colorectal carcinoma
patients. Cancer Sci 98:1113–1119
46. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D,
O’Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK,
Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin,
and bevacizumab in patients with metastatic gastric or gastroesopha-
geal junction adenocarcinoma. J Clin Oncol 24:5201–5206
47. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F,
Yang D, Toh Y, Yamana H, Itoh K (1998) A gene encoding anti-
genic peptides of human squamouscell carcinoma recognized by
cytotoxic T lymphocytes. J Exp Med 187:277–288
48. Somasundaram R, Robbins P, Moonka D, Loh E, Marincola F,
Patel A, Guerry D, Herlyn D (2000) CD4(+), HLA class I-restricted,
cytolytic T-lymphocyte clone against primary malignant
melanoma cells. Int J Cancer 85:253–259
49. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N,
Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S,
Harstrick A, Baselga J (2004) Phase I study of the humanized
antiepidermal growth factor receptor monoclonal antibody
EMD72000 in patients with advanced solid tumors that express the
epidermal growth factor receptor. J Clin Oncol 22:175–184
50. Vergelli M, Hemmer B, Muraro PA, Tranquilli L, Biddison WE,
Sarin A, McFarland HF, Martin R (1997) Human autoreactive
CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated
pathways for target cell lysis. J Immunol 158:2756–2761
51. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto
H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K (1999)
IdentiWcation of a gene coding for a protein possessing shared
tumor epitopes capable of inducing HLAA24-restricted cytotoxic
T lymphocytes in cancer patients. Cancer Res 59:4056–4063123
